OPKO Health, Inc. (OPK) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Lut Ming Cheng
JPMorgan Chase & Co, Research Division

Good afternoon, and welcome back. Thanks for joining us for another session at the 44th JPMorgan Healthcare Conference. I’m Brian Cheng. I’m one of the senior biotech analysts here at the firm. On stage, we have the team from OPKO Health. And here, the session here is a fireside session with the team. Maybe the OPKO team can introduce themselves, who do we have on this stage?

Elias Zerhouni
President & Vice Chairman

Sorry. Can you hear me okay?

Lut Ming Cheng
JPMorgan Chase & Co, Research Division

Yes.

Elias Zerhouni
President & Vice Chairman

I’m Elias Zerhouni, I’m the President of OPKO Health. I became President of OPKO Health because I co-founded a company called ModeX Therapeutics, which was acquired by OPKO Health in 2022. As part of that, I ended up being President of the acquiring company. And I’m a former Head of R&D at Sanofi, I’m a former Head of NIH and I was also a former academic at Johns Hopkins University.

Adam Logal
Senior VP & CFO

And I’m Adam Logal, I’m the CFO of OPKO.

Lut Ming Cheng
JPMorgan Chase & Co, Research Division

Elias, it would be great to kick off our conversation here. For those of you who don’t — for those people that are in the audience who don’t fully know the OPKO Health story, it would be great to get an overview of what you’re working on. And if you can go through different components of the business and how you’re thinking